Click on headlines below to download research
Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration…
FY22 was an exceptional year for Amoéba in which it secured regulatory approval in the United States and a recommendation for approval in the European…
During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance…